MicroPort Scientific Corporation
MicroPort®’s Firehawk® Drug Eluting Stent Achieves Primary Endpoint and Shows Very Promising Results From TARGET All-Comers Clinical Trial
5/23/18: "Data from the TARGET AC trial, which included the most complex patient real world population in Europe, demonstrated exceptional performance and safety of the Firehawk® stent," said William Wijns, M.D., PhD, National University of Ireland Galway, Ireland, and principal investigator for the study. "With this European clinical data set, Firehawk® has the potential to positively impact patient care by further reducing the risk of late adverse events and the need for device-mandated prolonged dual antiplatelet therapy, which is often associated with a higher risk of bleeding as well as increased patient treatment cost."
Lombard Medical and MicroPort Scientific Corporation Finalize Strategic Partnership Agreements Aorfix™, the only stent graft to hold global...